Related Experiment Video
Updated: Apr 25, 2026

Author Spotlight: Innovative Methods in Lymphedema and Hypertension Research
Published on: March 22, 2024
Hemodynamic effects of nifedipine tocolysis
Kelly Yamasato1, Janet Burlingame, Bliss Kaneshiro
1Department of Obstetrics, Gynecology and Women's Health, John A Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Nifedipine tocolysis in non-hypertensive women caused a slight decrease in blood pressure and an increase in heart rate. Tachycardia rates rose, but hypotension remained unaffected, indicating nifedipine
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Cardiovascular Physiology
Background:
- Tocolysis is used to inhibit preterm labor.
- Nifedipine is a commonly used tocolytic agent.
- Understanding its hemodynamic effects in non-hypertensive women is crucial for safe administration.
Purpose of the Study:
- To evaluate the impact of nifedipine tocolysis on blood pressure and heart rate.
- To assess hemodynamic changes in non-hypertensive women receiving nifedipine.
- To determine the safety profile of nifedipine in this patient population.
Main Methods:
- Retrospective study (2001-2011) of 138 non-hypertensive women receiving nifedipine.
- Comparison of blood pressure and heart rate measurements at various intervals post-nifedipine initiation.
- Review of charts for hypotension-related emergent deliveries.
Main Results:
- Mean systolic and diastolic blood pressure decreased by 5 mmHg over 8 hours (P < 0.001).
- Mean heart rate increased by 4 bpm (P < 0.001), with increased tachycardia rates.
- No significant changes in blood pressure within 120 minutes; hypotension rates were unchanged.
Conclusions:
- Nifedipine tocolysis induces mild hemodynamic alterations in non-hypertensive women.
- Increased tachycardia is observed, but hypotension is not a significant concern.
- Nifedipine appears generally safe for tocolysis in non-hypertensive individuals.
More Related Videos
11:59In Vivo Real-Time Study of Drug Effects on Carotid Blood Flow in the Ovine Fetus
Published on: April 28, 2023
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
Related Concept Videos
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Cardiac Catheterization IV: Nursing Management
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: β-Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers